{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06428097",
            "orgStudyIdInfo": {
                "id": "23-39323"
            },
            "organization": {
                "fullName": "University of California, San Francisco",
                "class": "OTHER"
            },
            "briefTitle": "Levothyroxine Supplementation for Heart Transplant Recipients",
            "officialTitle": "Levothyroxine Supplementation for Heart Transplant Recipients: A Randomized Control Trial",
            "acronym": "Levo",
            "therapeuticArea": [
                "Cardiovascular"
            ],
            "study": "levothyroxine-supplementation-for-heart-transplant-recipients"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-05",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-03-29",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2027-03-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2027-03-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-05-03",
            "studyFirstSubmitQcDate": "2024-05-22",
            "studyFirstPostDateStruct": {
                "date": "2024-05-24",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-05-29",
            "lastUpdatePostDateStruct": {
                "date": "2024-05-31",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of California, San Francisco",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false,
            "isUsExport": true
        },
        "descriptionModule": {
            "briefSummary": "This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine.",
            "detailedDescription": "Studies have shown that thyroid hormone results in a higher number of organs available for transplant. Increasingly, thyroid hormone supplementation is used amongst transplant donors. However, it is not the current standard of practice to supplement recipients without a prior medical history of hypothyroidism with levothyroxine. Two large retrospective studies have demonstrated improved 30-days survival and lower risk of all-cause mortality for heart transplant recipients who receive levothyroxine in the post-operative context. No randomized trials have tested this hypothesis and so the investigators aim to trial the use of levothyroxine for heart transplant recipients at University of California San Francisco using a double-blinded and placebo controlled randomized control trial study design. This will be a prospective, randomized study performed at a single tertiary referral academic medical center (University of California San Francisco, CA), evaluating the survival benefits of levothyroxine compared with no levothyroxine for patients who have undergone heart transplant. It will be double-blinded and placebo-control; participants will be randomized to receive levothyroxine or receive no levothyroxine."
        },
        "conditionsModule": {
            "conditions": [
                "Heart Transplant Failure",
                "Heart Transplant Infection"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "DOUBLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 97,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Levothyroxine",
                    "type": "EXPERIMENTAL",
                    "description": "Patients will be double-blinded and randomized to receive levothyroxine.",
                    "interventionNames": [
                        "Drug: Levothyroxine"
                    ]
                },
                {
                    "label": "No Levothyroxine",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Patients will be double-blinded and randomized to receive no levothyroxine. The placebo will be normal saline.",
                    "interventionNames": [
                        "Drug: Normal saline"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Levothyroxine",
                    "description": "Dosing will be based on pre-existing protocols in the setting of organ donation.This will be the protocol for the first 18-38 hours starting intra-operatively after the donated heart is sewn in.",
                    "armGroupLabels": [
                        "Levothyroxine"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Normal saline",
                    "description": "Placebo will be normal saline and will be dosed at the same rate and time as the study drug.",
                    "armGroupLabels": [
                        "No Levothyroxine"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of participants who receive Levothyroxine's vasopressor use compared to number of participants who receive normal saline's vasopressor use.",
                    "description": "Measured using the vasoactive-inotropic score (VIS) scale.\n\nVIS calculation: dopamine dose (\u03bcg/kg/min) + dobutamine dose (\u03bcg/kg/min) + 100 \u00d7 epinephrine dose (\u03bcg/kg/min) + 10 \u00d7 milrinone dose (\u03bcg/kg/min) + 10 000 \u00d7 vasopressin dose (unit/kg/min) + 100 \u00d7 norepinephrine dose (\u03bcg/kg/min)",
                    "timeFrame": "35 months total completion, 18 months accrual, 12 months follow up and 5 months data analysis"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Do the participants receiving levothyroxine experience lower frequencies of primary graft dysfunction?",
                    "description": "Measured as a yes or no diagnosis.",
                    "timeFrame": "35 months total completion, 18 months accrual, 12 months follow up and 5 months data analysis"
                },
                {
                    "measure": "Does the total vasoactive-inotropic score (VIS) decrease for patients who receive levothyroxine?",
                    "description": "Measured using the vasoactive-inotropic score (VIS) scale.\n\nVIS calculation: dopamine dose (\u03bcg/kg/min) + dobutamine dose (\u03bcg/kg/min) + 100 \u00d7 epinephrine dose (\u03bcg/kg/min) + 10 \u00d7 milrinone dose (\u03bcg/kg/min) + 10 000 \u00d7 vasopressin dose (unit/kg/min) + 100 \u00d7 norepinephrine dose (\u03bcg/kg/min)",
                    "timeFrame": "35 months total completion, 18 months accrual, 12 months follow up and 5 months data analysis"
                },
                {
                    "measure": "Do the participants have improved cardiac output?",
                    "description": "Cardiac output is calculated using stroke volume and heart rate and measured in liters/minute.\n\n(Cardiac output = stroke volume x heart rate)",
                    "timeFrame": "35 months total completion, 18 months accrual, 12 months follow up and 5 months data analysis"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n1. Participants must be listed for heart transplantation\n2. Age \u226518 years\n3. Ability to understand and the willingness to sign a written informed consent document.\n\nExclusion Criteria:\n\n1. Patients with pre-existing thyroid related condition including hypothyroidism, hyperthyroidism and malignancy\n2. Patients with a known allergy or intolerance to levothyroxine\n3. Patients participating in another study evaluating an investigational drug within the past 30 days.",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Lea Daran",
                    "role": "CONTACT",
                    "phone": "415-502-4320",
                    "email": "Lea.daran@ucsf.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jason Smith, MD",
                    "affiliation": "University of California, San Francisco",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of California, San Francisco",
                    "status": "RECRUITING",
                    "city": "San Francisco",
                    "state": "California",
                    "zip": "94143",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Lea Daran",
                            "role": "CONTACT",
                            "phone": "415-502-4320",
                            "email": "Lea.daran@ucsf.edu"
                        },
                        {
                            "name": "Jason Smith, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 37.77493,
                        "lon": -122.41942
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "YES"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M10283",
                    "name": "Infections",
                    "relevance": "LOW"
                },
                {
                    "id": "M6368",
                    "name": "Communicable Diseases",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC01",
                    "name": "Infections"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                }
            ]
        }
    },
    "hasResults": false
}